2US0 Stock Chart & Stats
€4.73
€0.00(0.00%)
At close: 4:00 PM EDT
€4.73
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.54 - €4.73
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€14.62M
Enterprise Value€31.14
Total Cash (Recent Filing)€29.74M
Total Debt (Recent Filing)€4.92M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.07
Shares Outstanding4,068,951
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.37Price Target Upside267.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive SIM0505 Phase 1 DataRobust early efficacy (55% ORR) and manageable safety in a first‑in‑human ADC provide durable de‑risking of the CDH6 program. Positive Phase 1 readouts support a development path into registrational studies or partnerships, improving long‑term commercial and licensing optionality.
Low Financial LeverageModest debt relative to equity reduces refinancing and solvency pressure, giving the company structural financial flexibility. Low leverage supports ability to pursue strategic transactions or secure non‑dilutive funding and cushions execution risk during clinical development.
Merger + $320M PIPE Improves Funding And StrategyThe merger and concurrent $320M financing materially extend funding visibility and pivot the combined entity to a high‑potential oral IL‑23 franchise. Coupled with experienced Avere leadership and licensing deals, this structural shift strengthens prospects for late‑stage development and commercialization execution.
Bears Say
No Revenue; Sustained Large LossesPersistent zero product revenue and large recurring losses indicate the company remains precommercial and reliant on external funding. Over the medium term this limits reinvestment, risks continued equity erosion, and means program advancement is contingent on financing or partnerships rather than internal cash generation.
Severe Dilution And Control Transfer From MergerThe transaction materially shifts ownership and control to Avere and PIPE investors, sharply diluting legacy holders and concentrating strategic decision‑making externally. This structural transfer reduces legacy shareholder upside and makes future returns dependent on new management's priorities and milestone monetizations.
Finite Cash Runway Amid Ongoing Cash BurnA stated cash runway into early 2027 combined with materially negative operating cash flow creates recurring financing necessity. Reliance on periodic financings or milestone receipts increases dilution risk and can constrain strategic options or trial timelines if expected funding sources are delayed or limited.
NextCure News
2US0 FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was €4.54 and its highest was €4.73 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is €14.62M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were NextCure Inc’s earnings last quarter?
Currently, no data Available
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,068,951 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in DE:2US0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
2US0 Stock 12 Month Forecast
Average Price Target
€17.37
▲(267.33% Upside)